Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Approved to Launch BTK Inhibitor in China for Two Cancer Indications

publication date: Jun 4, 2020

BeiGene, a Beijing cancer biotech, announced China's NMPA approved its BTK inhibitor, Brukinsa™ (zanubrutinib), for two cancer indications: chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). All indications are for second-line treatment in adult patients. In late 2019, Brukinsa was approved in the US to treat MCL. Brukinsa is the second BeiGene candidate to be commercialized. The company's anti-PD-1 antibody tislelizumab was approved in China, also in late 2019, as a third-line treatment for classical Hodgkin lymphoma (cHL). More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.